Sadly investors probably care very little from a financial position as to whether a drug works or not, as their exit usually happens somewhere between trials at Phase 1 and Phase 2. Earlier in the longevity market because it is hot.
I've put together Request for Startup lists for the longevity industry for the past few years, based on fairly detailed insight into the state of the science.
https://www.fightaging.org/archives/2019/02/request-for-star...
https://www.fightaging.org/archives/2017/12/request-for-star...
https://www.fightaging.org/archives/2016/12/request-for-star...
Because things move slowly in biotech, just about everything in these documents except for more senolytics is still valid.